Novel Indazole Non-Nucleoside Reverse Transcriptase Inhibitors Using Molecular Hybridization Based on Crystallographic Overlays

Journal of Medicinal Chemistry
2009.0

Abstract

A major problem associated with non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of HIV is their lack of resilience to mutations in the reverse transcriptase (RT) enzyme. Using structural overlays of the known inhibitors efavirenz and capravirine complexed in RT as a starting point, and structure-based drug design techniques, we have created a novel series of indazole NNRTIs that possess excellent metabolic stability and mutant resilience.

Knowledge Graph

Similar Paper

Novel Indazole Non-Nucleoside Reverse Transcriptase Inhibitors Using Molecular Hybridization Based on Crystallographic Overlays
Journal of Medicinal Chemistry 2009.0
Pyrazole NNRTIs 1: Design and initial optimisation of a novel template
Bioorganic & Medicinal Chemistry Letters 2009.0
Design of Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase with Improved Drug Resistance Properties. 1.
Journal of Medicinal Chemistry 2004.0
Design of Annulated Pyrazoles as Inhibitors of HIV-1 Reverse Transcriptase
Journal of Medicinal Chemistry 2008.0
Design of Non-nucleoside Inhibitors of HIV-1 Reverse Transcriptase with Improved Drug Resistance Properties. 2.
Journal of Medicinal Chemistry 2004.0
Synthesis and biological activity of new pyridone diaryl ether non-nucleoside inhibitors of HIV-1 reverse transcriptase
MedChemComm 2010.0
Discovery of novel benzimidazolones as potent non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains
Bioorganic & Medicinal Chemistry Letters 2007.0
Structural optimization of N1-aryl-benzimidazoles for the discovery of new non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains
Bioorganic & Medicinal Chemistry 2018.0
Specific Targeting of Highly Conserved Residues in the HIV-1 Reverse Transcriptase Primer Grip Region. 2. Stereoselective Interaction to Overcome the Effects of Drug Resistant Mutations
Journal of Medicinal Chemistry 2009.0
Design, Synthesis, and SAR of a Novel Pyrazinone Series with Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitory Activity
Journal of Medicinal Chemistry 2005.0